Celestica, Inc. (CLS) is Attracting Investor Attention: Here is What You Should Know
Celestica (NYSE: CLS) has recently been on Zacks.com’s list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock’s performance in the near future. read more
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
4D Molecular’s 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment. read more
LENZ Therapeutics’ Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People
LENZ Therapeutics’ VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025. read more
Exxon Mobil Hits Record Production, CEO Reaffirms Hunt For Value-Driven Deals
Exxon Mobil Corp. (XOM) Q2 earnings beat estimates with $7.1B profit on record production and revenues, plans for growth and acquisitions. read more
